Summit Global Investments lowered its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 31.3% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 35,070 shares of the biopharmaceutical company's stock after selling 16,010 shares during the quarter. Summit Global Investments' holdings in Gilead Sciences were worth $3,930,000 at the end of the most recent reporting period.
A number of other large investors have also added to or reduced their stakes in the stock. HHM Wealth Advisors LLC boosted its holdings in shares of Gilead Sciences by 118.5% in the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 154 shares in the last quarter. YANKCOM Partnership acquired a new stake in shares of Gilead Sciences in the 4th quarter valued at $28,000. Crews Bank & Trust acquired a new stake in shares of Gilead Sciences in the 4th quarter valued at $31,000. Stephens Consulting LLC boosted its holdings in shares of Gilead Sciences by 325.0% in the 4th quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company's stock valued at $31,000 after purchasing an additional 260 shares in the last quarter. Finally, Newbridge Financial Services Group Inc. acquired a new stake in shares of Gilead Sciences in the 4th quarter valued at $33,000. Institutional investors and hedge funds own 83.67% of the company's stock.
Gilead Sciences Trading Down 0.7%
Shares of GILD stock traded down $0.76 during mid-day trading on Friday, hitting $110.35. The company's stock had a trading volume of 11,912,582 shares, compared to its average volume of 7,714,787. The company's fifty day simple moving average is $105.49 and its 200-day simple moving average is $100.83. Gilead Sciences, Inc. has a 52 week low of $62.69 and a 52 week high of $119.96. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. The company has a market cap of $137.27 billion, a PE ratio of 298.24, a P/E/G ratio of 0.71 and a beta of 0.26.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, topping the consensus estimate of $1.77 by $0.04. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The firm had revenue of $6.67 billion during the quarter, compared to analyst estimates of $6.77 billion. During the same period last year, the company posted ($1.32) EPS. The business's quarterly revenue was down .3% on a year-over-year basis. As a group, equities research analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.
Gilead Sciences Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Friday, June 13th will be given a $0.79 dividend. This represents a $3.16 annualized dividend and a dividend yield of 2.86%. The ex-dividend date of this dividend is Friday, June 13th. Gilead Sciences's dividend payout ratio (DPR) is presently 66.53%.
Insider Transactions at Gilead Sciences
In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the firm's stock in a transaction that occurred on Tuesday, April 15th. The stock was sold at an average price of $106.40, for a total value of $266,000.00. Following the completion of the sale, the chief financial officer now owns 168,174 shares of the company's stock, valued at approximately $17,893,713.60. This trade represents a 1.46% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Johanna Mercier sold 28,000 shares of the firm's stock in a transaction that occurred on Thursday, May 22nd. The shares were sold at an average price of $107.52, for a total value of $3,010,560.00. Following the completion of the sale, the insider now directly owns 121,152 shares of the company's stock, valued at $13,026,263.04. This trade represents a 18.77% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 50,929 shares of company stock valued at $5,644,780. Corporate insiders own 0.27% of the company's stock.
Analyst Ratings Changes
A number of brokerages have weighed in on GILD. The Goldman Sachs Group raised their target price on Gilead Sciences from $85.00 to $96.00 and gave the company a "neutral" rating in a report on Wednesday, February 12th. Cantor Fitzgerald began coverage on Gilead Sciences in a report on Tuesday, April 22nd. They set an "overweight" rating and a $125.00 price objective on the stock. BMO Capital Markets raised their price objective on Gilead Sciences from $110.00 to $115.00 and gave the company an "outperform" rating in a report on Wednesday, February 12th. Morgan Stanley raised their price objective on Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a report on Friday, April 25th. Finally, Needham & Company LLC reissued a "hold" rating on shares of Gilead Sciences in a report on Wednesday, May 21st. Nine equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat, Gilead Sciences currently has a consensus rating of "Moderate Buy" and a consensus target price of $110.55.
Get Our Latest Stock Analysis on GILD
Gilead Sciences Company Profile
(
Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
See Also
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
